We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cyprotex Launches Cloe® Screen Assay to Improve the Prediction of in vivo Pharmacokinetics
Product News

Cyprotex Launches Cloe® Screen Assay to Improve the Prediction of in vivo Pharmacokinetics

Cyprotex Launches Cloe® Screen Assay to Improve the Prediction of in vivo Pharmacokinetics
Product News

Cyprotex Launches Cloe® Screen Assay to Improve the Prediction of in vivo Pharmacokinetics


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cyprotex Launches Cloe® Screen Assay to Improve the Prediction of in vivo Pharmacokinetics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cyprotex has announced that it has enhanced the Cloe® Screen product offering to include an in vitro assay that assesses the extent to which a compound binds to liver microsomes. When used in conjunction with microsomal stability data, correction for microsomal binding can improve the prediction of a compound’s in vivo clearance and potential for drug-drug interactions.

The Cyprotex Cloe® Screen microsomal binding assay was designed in response to requests from biotechnology and pharmaceutical companies who work with Cyprotex’ to evaluate potential drug candidates.

Mr. Robert Morrison Atwater, Cyprotex’ Chief Executive Officer, comments on the launch of the new service, “Once again Cyprotex proves itself to be foremost in the provision of in vitro ADMET services. By offering this service we are adding to our extensive portfolio of services and reinforcing Cyprotex’ position as a leader within the industry. Similarly to existing Cloe® Screen assays, the microsomal binding assay is invaluable in enabling companies to make informed decisions when selecting compounds to progress further within the drug discovery process.”

Advertisement